What is Bromantane?

Bromantane (N-(4-bromophenyl)adamantan-2-amine, also called Ladasten, Bromantan, and N-(2-adamantyl)-N-(4-bromophenyl)amine; CAS 87913-26-6) is a synthetic adamantane secondary amine. It is an actoprotector-class research compound built on a rigid tricyclo[3.3.1.1^3,7]decane (adamantane) core with a para-bromophenyl substituent on the 2-amino nitrogen. Bromantane is not a peptide and not an amino acid, even though some marketplace searches label it a “Bromantane peptide.” Its activity profile in the published molecular pharmacology literature is tied to catecholamine-pathway enzyme expression rather than to a peptide backbone.

Published actoprotector reviews describe Bromantane as acting upstream of monoamine release: by supporting transcriptional upregulation of Tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine biosynthesis, and by modulating GABA-transporter expression in GABAergic pathways (Oliynyk & Oh, 2012, PMC3762282). What Bromantane does at the enzyme-and-gene-expression level is therefore chemistry-first: a lipophilic adamantane–bromoaniline scaffold whose reported targets are biosynthetic enzymes and transporter transcripts, not a peptide receptor epitope.

Batch-verified at Modern Aminos, Bromantane is supplied in 2 laboratory formats:

• 25 mg dry-fill capsules, 60 units per capsule bottle (Form option “25MG Dry-Fill (x60)”)
• 50 mg/mL liquid, 30 mL (Form option “50MG/ML (30ML)”)

Laboratories building catecholamine-pathway and adamantane structure–activity assay panels often place Bromantane next to other public reference listings such as L-THP, PRL-8-53, TAK-653, and BPAP, as well as Phenylpiracetam Hydrazide, Noopept, and Sunifiram. For a closer look at whether Bromantane is a peptide, see Is Bromantane a Peptide? N-(4-bromophenyl)adamantan-2-amine Explained.

Chemical and Molecular Data for Bromantane

Identity fields are drawn from PubChem CID 4660557; purity and quantity values come from the lot certificates in the Certificate of Analysis tab.

What are the Mechanisms of Action?

The biochemical targets and pathway logic of Bromantane in laboratory research include:

• Adamantane–bromoaniline scaffold: Bromantane joins a lipophilic adamantane cage to a 4-bromoaniline secondary amine. PubChem records the connectivity SMILES C1C2CC3CC1CC(C2)C3NC4=CC=C(C=C4)Br, formula C₁₆H₂₀BrN, and InChIKey LWJALJDRFBXHKX-UHFFFAOYSA-N for CID 4660557. The para-bromoaryl amine is the structural handle that distinguishes Bromantane from related adamantane amines such as chlodantane (a chloro analog discussed separately in actoprotector reviews).
• Tyrosine hydroxylase (TH) transcriptional upregulation: Actoprotector pharmacology reviews summarize Bromantane’s primary reported action as increasing activity in dopaminergic pathways through facilitation of TH gene expression, elevating the biosynthetic capacity for L-DOPA and downstream catecholamines without framing the compound as a monoamine-releasing stimulant (Oliynyk & Oh, 2012). TH is the rate-limiting enzyme of catecholamine biosynthesis, so a transcriptional effect sits upstream of vesicle loading and transporter cycling.
• GABA-transporter transcript modulation: The same review class summarizes strengthening of GABA-ergic mediation with reduced expression of genes that supervise GABA-transporter synthesis and reuptake. That places a second, inhibitory-tone pathway alongside the catecholamine-biosynthesis axis, which is why Bromantane is often discussed as dual catecholaminergic–GABAergic chemistry rather than as a simple releaser.
• High lipophilicity and tissue distribution chemistry: Bromantane is described as highly lipophilic, distributing into lipid-rich compartments and depositing in adipose stores, with hepatic metabolism and prolonged metabolite detectability noted in the actoprotector literature (Oliynyk & Oh, 2012). Those physicochemical traits matter for assay design (solvent choice, adsorption, carryover) even when no receptor Ki is published.
• Data gap — no recombinant TH IC₅₀ or receptor Ki panel: Unlike enzyme inhibitors with published recombinant IC₅₀ tables, Bromantane does not have a PubMed-indexed recombinant TH inhibition/activation constant or a clean GPCR binding panel. Claims on this page stay at the pathway-and-scaffold level supported by the actoprotector review and PubChem identity; they do not invent binding numbers.

What Does Published Research Show for Bromantane?

Peer-reviewed literature on Bromantane centers on adamantane chemistry, actoprotector class definition, and catecholamine-pathway enzyme expression:

• Actoprotector class and structure (PMC): Oliynyk and Oh define actoprotectors as synthetic adaptogens and place Bromantane (N-(2-adamantyl)-N-(para-bromophenyl)-amine; commercial name Ladasten in the Russian literature) among the adamantane-derivative subclass, with bemitil as the benzimidazole counterpart (PMC3762282).
• Pathway logic (PMC): The same review summarizes dopaminergic-system implementation and GABA-ergic mediation via reduced GABA-transporter gene expression — pathway framing used here without study-model or performance claims (PMC3762282).
• Chemical directory and structure verification (PubChem): PubChem CID 4660557 lists CAS 87913-26-6, formula C₁₆H₂₀BrN, MW 306.24, exact mass 305.07791 Da, IUPAC N-(4-bromophenyl)adamantan-2-amine, InChIKey LWJALJDRFBXHKX-UHFFFAOYSA-N, and UNII N1ILS53XWK (PubChem 4660557).
• Analytical quality: Why chromatographic testing matters for reference materials is covered in Modern Aminos’ note on HPLC testing.

How does Bromantane compare to other compounds?

To map catecholamine-pathway and neurochemistry tools, researchers compare Bromantane against other public reference compounds available at Modern Aminos:

Frequently Asked Questions (FAQs)